499 related articles for article (PubMed ID: 27272808)
1. Vascular Endothelial Growth Factor in Plasma and Pleural Effusion Is a Biomarker for Outcome After Bevacizumab plus Carboplatin-Paclitaxel Treatment for Non-small Cell Lung Cancer with Malignant Pleural Effusion.
Tamiya M; Tamiya A; Yasue T; Nakao K; Omachi N; Shiroyama T; Tani E; Hamaguchi M; Morishita N; Suzuki H; Okamoto N; Okishio K; Kawaguchi T; Atagi S; Hirashima T
Anticancer Res; 2016 Jun; 36(6):2939-44. PubMed ID: 27272808
[TBL] [Abstract][Full Text] [Related]
2. Bevacizumab plus chemotherapy in nonsquamous non-small cell lung cancer patients with malignant pleural effusion uncontrolled by tube drainage or pleurodesis: A phase II study North East Japan Study group trial NEJ013B.
Noro R; Kobayashi K; Usuki J; Yomota M; Nishitsuji M; Shimokawa T; Ando M; Hino M; Hagiwara K; Miyanaga A; Seike M; Kubota K; Gemma A;
Thorac Cancer; 2020 Jul; 11(7):1876-1884. PubMed ID: 32421226
[TBL] [Abstract][Full Text] [Related]
3. Phase2 study of bevacizumab with carboplatin-paclitaxel for non-small cell lung cancer with malignant pleural effusion.
Tamiya M; Tamiya A; Yamadori T; Nakao K; Asami K; Yasue T; Otsuka T; Shiroyama T; Morishita N; Suzuki H; Okamoto N; Okishio K; Kawaguchi T; Atagi S; Kawase I; Hirashima T
Med Oncol; 2013; 30(3):676. PubMed ID: 23925664
[TBL] [Abstract][Full Text] [Related]
4. Intrapleural combination therapy with bevacizumab and cisplatin for non-small cell lung cancer‑mediated malignant pleural effusion.
Du N; Li X; Li F; Zhao H; Fan Z; Ma J; Fu Y; Kang H
Oncol Rep; 2013 Jun; 29(6):2332-40. PubMed ID: 23525453
[TBL] [Abstract][Full Text] [Related]
5. A phase II study of bevacizumab with carboplatin-pemetrexed in non-squamous non-small cell lung carcinoma patients with malignant pleural effusions: North East Japan Study Group Trial NEJ013A.
Usui K; Sugawara S; Nishitsuji M; Fujita Y; Inoue A; Mouri A; Watanabe H; Sakai H; Kinoshita I; Ohhara Y; Maemondo M; Kagamu H; Hagiwara K; Kobayashi K;
Lung Cancer; 2016 Sep; 99():131-6. PubMed ID: 27565928
[TBL] [Abstract][Full Text] [Related]
6. Bevacizumab plus chemotherapy for advanced non-squamous non-small-cell lung cancer with malignant pleural effusion.
Kitamura K; Kubota K; Ando M; Takahashi S; Nishijima N; Sugano T; Toyokawa M; Miwa K; Kosaihira S; Noro R; Minegishi Y; Seike M; Yoshimura A; Gemma A
Cancer Chemother Pharmacol; 2013 Feb; 71(2):457-61. PubMed ID: 23178954
[TBL] [Abstract][Full Text] [Related]
7. Phase 2 study of bevacizumab plus carboplatin/nab-paclitaxel followed by bevacizumab plus nab-paclitaxel for non-squamous non-small cell lung cancer with malignant pleural effusion.
Tamiya M; Tamiya A; Suzuki H; Taniguchi Y; Katayama K; Minomo S; Nakao K; Takeuchi N; Matsuda Y; Naito Y; Shiroyama T; Okamoto N; Okishio K; Kumagai T; Atagi S; Imamura F; Hirashima T
Invest New Drugs; 2021 Aug; 39(4):1106-1112. PubMed ID: 33544282
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of Natriuretic Peptide in Non-small Cell Lung Cancer Patients Treated with Bevacizumab Together with Carboplatin-Paclitaxel: A Prospective Study.
Otsuka T; Nojiri T; Minami S; Hosoda H; Kuroyama M; Hirata H; Nakanishi K; Yamamoto S; Komuta K; Kangawa K; Kijima T
Anticancer Res; 2017 Jul; 37(7):3505-3512. PubMed ID: 28668839
[TBL] [Abstract][Full Text] [Related]
9. Improved tumor vascularization after anti-VEGF therapy with carboplatin and nab-paclitaxel associates with survival in lung cancer.
Heist RS; Duda DG; Sahani DV; Ancukiewicz M; Fidias P; Sequist LV; Temel JS; Shaw AT; Pennell NA; Neal JW; Gandhi L; Lynch TJ; Engelman JA; Jain RK
Proc Natl Acad Sci U S A; 2015 Feb; 112(5):1547-52. PubMed ID: 25605928
[TBL] [Abstract][Full Text] [Related]
10. A correlative biomarker analysis of the combination of bevacizumab and carboplatin-based chemotherapy for advanced nonsquamous non-small-cell lung cancer: results of the phase II randomized ABIGAIL study (BO21015).
Mok T; Gorbunova V; Juhasz E; Szima B; Burdaeva O; Orlov S; Yu CJ; Archer V; Hilton M; Delmar P; Pallaud C; Reck M
J Thorac Oncol; 2014 Jun; 9(6):848-55. PubMed ID: 24807156
[TBL] [Abstract][Full Text] [Related]
11. Outcomes of bevacizumab combined with chemotherapy in lung adenocarcinoma-induced malignant pleural effusion.
Tao H; Meng Q; Li M; Shi L; Tang J; Liu Z
Thorac Cancer; 2018 Feb; 9(2):298-304. PubMed ID: 29297985
[TBL] [Abstract][Full Text] [Related]
12. Bevacizumab for ramucirumab refractory malignant pleural effusion in non-small cell lung cancer: a case report and review of the literature.
Mori R; Fujimoto D; Ito M; Tomii K
Oncotarget; 2017 Jul; 8(29):48521-48524. PubMed ID: 28591698
[TBL] [Abstract][Full Text] [Related]
13. The clinical efficacy and safety of paclitaxel combined with avastin for NSCLC patients diagnosed with malignant pleural effusion.
Wang Z; Zheng Y; Fang Z
Rev Assoc Med Bras (1992); 2018 Mar; 64(3):230-233. PubMed ID: 29641777
[TBL] [Abstract][Full Text] [Related]
14. Diagnostic and prognostic values of endothelial-cell-specific molecule-1 with malignant pleural effusions in patients with non-small cell lung cancer.
Lu GJ; Shao CJ; Zhang Y; Wei YY; Xie WP; Kong H
Oncotarget; 2017 Jul; 8(30):49217-49223. PubMed ID: 28514746
[TBL] [Abstract][Full Text] [Related]
15. Role of bevacizumab in the management of the patient with malignant pleural effusion: more questions than answers.
Sabang RL; Gandhiraj D; Fanucchi M; Epelbaum O
Expert Rev Respir Med; 2018 Feb; 12(2):87-94. PubMed ID: 29235400
[TBL] [Abstract][Full Text] [Related]
16. Treatment of malignant pleural effusion in non-small cell lung cancer with VEGF-directed therapy.
Xiang Z; Deng X; He W; Yang Q; Ni L; Dehghan Shasaltaneh M; Maghsoudloo M; Yang G; Wu J; Imani S; Wen Q
Ann Med; 2022 Dec; 54(1):1357-1371. PubMed ID: 35543207
[TBL] [Abstract][Full Text] [Related]
17. Levels of vascular endothelial growth factor in serum and pleural fluid are independent predictors of survival in advanced non-small cell lung cancer: results of a prospective study.
Gkiozos I; Tsagouli S; Charpidou A; Grapsa D; Kainis E; Gratziou C; Syrigos K
Anticancer Res; 2015 Feb; 35(2):1129-37. PubMed ID: 25667503
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness of nanoparticle albumin-bound paclitaxel plus carboplatin in non-small lung cancer patients with malignant pleural effusion.
Koyama N; Watanabe Y; Iwai Y; Miwa C; Nagai Y; Aoshiba K; Nakamura H
Neoplasma; 2018; 65(1):132-139. PubMed ID: 29322797
[TBL] [Abstract][Full Text] [Related]
19. Combination use of paclitaxel and avastin enhances treatment effect for the NSCLC patients with malignant pleural effusion.
Qi N; Li F; Li X; Kang H; Zhao H; Du N
Medicine (Baltimore); 2016 Nov; 95(47):e5392. PubMed ID: 27893676
[TBL] [Abstract][Full Text] [Related]
20. A randomized clinical study to compare intrapleural infusion with intravenous infusion of bevacizumab in the management of malignant pleural effusion in patients with non-small-cell lung cancer.
Nie K; Zhang Z; You Y; Zhuang X; Zhang C; Ji Y
Thorac Cancer; 2020 Jan; 11(1):8-14. PubMed ID: 31726490
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
